| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 15.05. | Vaso Corporation Announces Financial Results for First Quarter of 2026 | 362 | GlobeNewswire (Europe) | PLAINVIEW, N.Y., May 15, 2026 (GLOBE NEWSWIRE) -- Vaso Corporation ("Vaso") (OTCQX: VASO), a leading MedTech company with a diversified business portfolio in network and IT services, professional... ► Artikel lesen | |
| 08.05. | VASO Corp - 8-K, Current Report | - | SEC Filings | ||
| 31.03. | VASO Corp - 10-K, Annual Report | - | SEC Filings | ||
| 31.03. | Vasomedical reports Q4 results, revenue flat at $27M | 1 | Seeking Alpha | ||
| 31.03. | Vaso Corporation Announces Financial Results for Fourth Quarter and Full Year 2025 | 178 | GlobeNewswire (Europe) | PLAINVIEW, N.Y., March 31, 2026 (GLOBE NEWSWIRE) -- Vaso Corporation ("Vaso") (OTCQX: VASO), a leading MedTech company with a diversified business portfolio in network and IT services, professional... ► Artikel lesen | |
| VASO Aktie jetzt für 0€ handeln | |||||
| 12.02. | VASO Corp - 8-K, Current Report | 1 | SEC Filings | ||
| 17.12.25 | Vaso Corporation Announces Fifth Extension of Sales Representation Agreement with GE HealthCare | 383 | GlobeNewswire (Europe) | Vaso Corporation137 Commercial StreetPlainview, New York 11803Tel: (516) 997-4600 Fax: (516) 997-2299 Investor Contact:Jonathan NewtonInvestor RelationsPhone: 516-997-4600 Email: jnewton@vasocorporation.com... ► Artikel lesen | |
| 19.11.25 | NANO-X IMAGING LTD: Nanox Reaches Agreement with Vaso Corporation to Acquire VasoHealthcare IT, Accelerating U.S. Rollout of AI Solutions | 541 | GlobeNewswire (Europe) | PETACH TIKVA, Israel, Nov. 19, 2025 (GLOBE NEWSWIRE) -- NANO-X IMAGING LTD ("Nanox" or the "Company", Nasdaq: NNOX), an innovative medical imaging technology company, today announced that the parties... ► Artikel lesen | |
| 14.11.25 | Vaso Corporation Announces Financial Results for Third Quarter of 2025 | 342 | GlobeNewswire (Europe) | PLAINVIEW, N.Y., Nov. 14, 2025 (GLOBE NEWSWIRE) -- Vaso Corporation ("Vaso") (OTCQX: VASO), a leading MedTech company with a diversified business portfolio in network and healthcare IT services, professional... ► Artikel lesen | |
| 02.09.25 | Telescope Innovations Corp.: Telescope Innovations Appoints Vaso Vlachos as Chief Operating Officer | 513 | Newsfile | Vancouver, British Columbia--(Newsfile Corp. - September 2, 2025) - Telescope Innovations Corp. (CSE: TELI) (OTCQB: TELIF) (FSE: J4U) ("Telescope Innovations", "Telescope", or the "Company"), a leader... ► Artikel lesen |
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BAYER | 47,000 | 0,00 % | Bayer und PORR werden für Produktionsanlage ausgezeichnet | ||
| ASTRAZENECA | 166,10 | +0,39 % | JEFFERIES stuft ASTRAZENECA auf 'Buy' | NEW YORK (dpa-AFX Analyser) - Das Analysehaus Jefferies hat die Einstufung für Astrazeneca mit einem Kursziel von 18000 Pence auf "Buy" belassen. Die anstehenden Phase-III-Daten der Studie gegen ATTR-Kardiomyopathie... ► Artikel lesen | |
| EYEPOINT | 12,600 | +5,00 % | Mizuho reiterates EyePoint stock rating on competitor timeline shift | ||
| IONIS PHARMACEUTICALS | 71,60 | +4,59 % | Ionis grants Recordati rights to zilganersen for Alexander disease | ||
| WAYLAND GROUP | - | - | EQS-News: Berger Montague (Canada) PC: Ankündigung der Anhörung zur Genehmigung des Vergleichs - Wayland Group Corp., Scott Langille, Gerhard Müller, Paul Pathak, Eric Silver, M. Stein, John Does 1-3, Canaccord Genuity Corp. und RF Securities Clearing LP | EQS-News: Berger Montague (Canada) PC
/ Schlagwort(e): Rechtssache/Sonstiges
ANKÜNDIGUNG DER ANHÖRUNG ZUR GENEHMIGUNG DES VERGLEICHS - KURZFASSUNG - WAYLAND... ► Artikel lesen | |
| CSPC PHARMA | 0,735 | -1,28 % | Dividendenbekanntmachungen (24.06.2026) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) AH REALTY TRUST INC US04208T1088 0,14 USD 0,1229 EUR AMBEV SA ADR US02319V1035 0,0091 USD 0,008 EUR ARLANDASTAD GROUP AB SE0016276851 1... ► Artikel lesen | |
| SELLAS LIFE SCIENCES | 10,750 | -0,92 % | DesignRush: Brooke Sellas Joins DesignRush Podcast on Social Media's Revenue Risk | Miami, Florida--(Newsfile Corp. - June 23, 2026) - The latest episode of the DesignRush Podcast features Brooke Sellas, founder and CEO of B Squared Media. The episode explores why companies risk... ► Artikel lesen | |
| MADRIGAL PHARMACEUTICALS | 457,90 | +1,48 % | Piper Sandler bestätigt Madrigal Pharmaceuticals Aktie mit Kursziel 900 US-Dollar | ||
| ACADIA PHARMACEUTICALS | 22,130 | -0,54 % | Acadia Pharmaceuticals Inc.: DAYBU (Trofinetide) vom CHMP für die Zulassung in der Europäischen Union empfohlen | - Die Entscheidung der Europäischen Kommission wird in den kommenden Monaten erwartet. - Im Falle einer Zulassung wird DAYBU die erste Behandlung von neurobehavioralen Symptomen des Rett-Syndroms... ► Artikel lesen | |
| CATALYST PHARMACEUTICALS | 27,300 | -1,44 % | CATALYST PHARMACEUTICALS, INC. - 8-K, Current Report | ||
| OPUS GENETICS | 3,400 | -3,41 % | Opus Genetics Aktie steigt nach Aufnahme in Russell Indizes | ||
| CHUGAI PHARMACEUTICAL | 40,090 | 0,00 % | Chugai Pharma Q1 Results Climb, Backs FY26 Outlook | TOKYO (dpa-AFX) - Japan's Chugai Pharmaceutical Co., Ltd. (CHGCF.PK, 4519.T) reported Friday higher profit and revenues for its first quarter, and maintained fiscal 2026 outlookIn the first... ► Artikel lesen | |
| SAVARA | 5,360 | +3,51 % | Savara Inc.: Savara Announces the U.K. Medicines and Healthcare Products Regulatory Agency (MHRA) Has Accepted the MOLBREEVI* Marketing Authorisation Application (MAA) for Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP) | -- MHRA's Acceptance Follows Acceptance/Validation of MOLBREEVI Biologics License Application (BLA) and MAA in Autoimmune PAP by the U.S. Food and Drug Administration (FDA) and the European Medicines... ► Artikel lesen | |
| ELITE PHARMACEUTICALS | - | - | Elite Pharmaceuticals, Inc.: Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss Fiscal Year 2026 Financial Results on June 30, 2026 | Northvale, New Jersey--(Newsfile Corp. - June 23, 2026) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty pharmaceutical company developing niche generic products... ► Artikel lesen | |
| GALECTIN THERAPEUTICS | 4,240 | -2,75 % | Galectin Therapeutics Inc.: Galectin Therapeutics Announces Positive Type C Meeting with the FDA for Belapectin in Patients with MASH Cirrhosis and Portal Hypertension | Galectin has reached agreement with the FDA on the primary endpoint and regulatory path forward for the potential full approval of belapectinCompany intends to file the Phase 3 protocol in Q3 2026... ► Artikel lesen |